Skip to NavigationSkip to content

Renewed BARDA backing boosts J&J’s COVID-19 vaccine funding by $1bn

Published on 17/11/20 at 12:46pm

Johnson & Johnson has said that it is injecting around $1 billion of funding into its research efforts to develop a COVID-19 vaccine, part of that sum coming from the US Government.

In an expansion of its current partnership with the Biomedical Advanced Research and Development Authority (BARDA), J&J is set to receive an additional $454 million from the authority to fund its ongoing Phase 3 studies of its adenovirus-based vaccine candidate in a single-dose formulation – a key factor that sets it apart from rival therapies from Moderna and Pfizer and BioNTech.

J&J’s pharmaceutical arm Janssen has also committed to investing $604 million to help fund the trial, which aims to enrol 60,000 participants in total.

This latest cash injection adds to previous investment made by both parties, who both opted to invest equal sums to a total of $1 billion back in March.

J&J also launched its second global COVID-19 vaccine this week. This one, however, will focus on testing the candidate in a two-dose formulation.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches